U

    Uniqure NV (QURE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $48.68
    -0.04 (-0.08%)

    Market Cap: $3.38B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(23/40)
    Avg Surprise
    -4.47%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.82
    Range$-1.06 - $-0.66
    9 analysts
    EPS Revisions
    2
    0
    7d
    3
    6
    30d
    EPS Estimate Drift
    90d ago$-0.79+4.6%
    60d ago$-0.75+8.7%
    30d ago$-0.81+1.4%
    7d ago$-0.80+2.5%
    Current$-0.82
    Revenue Consensus
    $5M
    Range$2M - $9M
    10 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.16
    Range$-2.03 - $-0.80
    9 analysts
    Revenue Consensus
    $7M
    Range$-237370 - $16M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.16---
    Sep 26EST
    		-$-0.82---
    Jun 26
    Reported Jul 29
    		$-1.22$-0.81-50.62%Miss-103.3%
    Mar 26
    Reported May 5
    		$-0.73$-0.75+2.67%Beat+0.0%
    Dec 25
    Reported Mar 2
    		$-0.47$-0.92+48.31%Beat+67.1%
    Sep 25
    Reported Nov 10
    		$-1.19$-0.75-58.67%Miss-41.7%
    Jun 25
    Reported Jul 29
    		$-0.60$-0.76+21.05%Beat+44.4%
    Mar 25
    Reported May 9
    		$-0.73$-0.93+21.51%Beat+42.1%
    Dec 24
    Reported Feb 27
    		$-1.44$-0.52-178.82%Miss+5.8%
    Sep 24
    Reported Nov 5
    		$-0.84$-0.93+9.68%Beat+52.0%
    Jun 24
    Reported Aug 1
    		$-1.08$-1.16+6.90%Beat+17.6%
    Mar 24
    Reported May 7
    		$-1.26$-1.16-8.62%Miss+14.9%
    Dec 23
    Reported Feb 28
    		$-1.53$-1.46-4.79%Miss-1120.0%
    Sep 23
    Reported Nov 7
    		$-1.75$-0.72-143.06%Miss-69.9%
    Jun 23
    Reported Aug 1
    		$-1.31N/A-146.62%Miss-57.8%
    Mar 23
    Reported May 9
    		$-1.48$-0.87-70.11%Miss-55.8%
    Dec 22
    Reported Feb 27
    		$0.15N/A+116.85%Beat-11.8%
    Sep 22
    Reported Nov 2
    		$-1.03$-1.11+7.21%Beat-51.5%
    Jun 22
    Reported Aug 8
    		$-0.83$-0.91+8.79%Beat-111.5%
    Mar 22
    Reported May 2
    		$-0.95$-0.79-20.25%Miss-26.7%
    Dec 21
    Reported Feb 25
    		$0.17N/A+120.99%Beat+1800.0%
    Sep 21
    Reported Oct 25
    		$-0.68$-0.91+25.27%Beat+33.3%
    Jun 21
    Reported Jul 26
    		$7.23$2.18+231.65%Beat+981.7%
    Mar 21
    Reported May 10
    		$-0.75$-0.77+2.60%Beat-29.3%
    Dec 20
    Reported Mar 1
    		$-0.01N/A-100.66%Miss+99.0%
    Sep 20
    Reported Oct 27
    		$-1.02$-0.76-34.21%Miss-96.2%
    Jun 20
    Reported Jul 30
    		$-0.82$-0.52-57.69%Miss-9.3%
    Mar 20
    Reported Apr 29
    		$-0.58$-0.73+20.55%Beat+12.1%
    Dec 19
    Reported Mar 2
    		$-0.96$-0.73-31.51%Miss-62.7%
    Sep 19
    Reported Oct 28
    		$-0.52$-0.74+29.73%Beat+0.0%
    Jun 19
    Reported Jul 29
    		$-0.75$-0.67-11.94%Miss-53.1%
    Mar 19
    Reported Apr 29
    		$-0.66$-0.63-4.76%Miss-34.7%
    Dec 18
    Reported Feb 28
    		$-0.59$-0.66+10.61%Beat+35.2%
    Sep 18
    Reported Nov 6
    		$-0.52$-0.54+3.70%Beat-52.9%
    Jun 18
    Reported Aug 8
    		$-0.49$-0.52+5.77%Beat+31.0%
    Mar 18
    Reported Apr 30
    		$-0.49$-0.61+19.67%Beat+33.8%
    Dec 17
    Reported Mar 14
    		$-0.91$-0.77-18.18%Miss-78.4%
    Sep 17
    Reported Nov 1
    		$-0.34$-0.54+37.04%Beat+37.0%
    Jun 17
    Reported Aug 8
    		$-0.71$-0.71+0.00%Beat-
    Mar 17
    Reported May 9
    		$-0.74$-0.58-27.59%Miss-
    Dec 16
    Reported Mar 15
    		$-0.51$-0.56+8.93%Beat-
    Sep 16
    Reported Nov 22
    		$-0.54$-0.77+29.87%Beat-

    Key Metrics

    Valuation
    P/E Ratio-13.47EV/EBITDA1.40x
    Price/FCF-19.96xFCF Yield-5.01%
    Profitability
    Profit Margin0.00%Operating Margin-872.00%
    ROE-157.60%ROIC-54.80%
    Financial Health
    Debt/Equity0.15xInterest Coverage-3.44x
    Current Ratio10.01xQuick Ratio10.01x
    Trading Statistics
    Beta0.94Avg Volume1.09M
    52-Week High$71.5052-Week Low$8.73

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$48.98
    SMA 20$47.47
    SMA 50$44.57
    SMA 200$28.04
    EMA 10$48.72
    EMA 20$47.32
    EMA 50$43.02
    EMA 200$31.83

    MACD

    Line: 1.99Signal: 2.10Hist: -0.11

    ADX

    ADX: 28.0+DI: 28.6-DI: 19.6

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down4.0
    PSAR$51.72

    Bollinger Bands

    Upper Band$51.63
    Lower Band$43.30
    %B Position1756%(Upper)
    Band Width0.65

    RSI (14-Day)

    Neutral
    58.8

    Momentum Oscillators

    Stoch %K63.6
    Stoch %D73.8
    Williams %R-40.5
    ROC (10d)1.5%
    Momentum0.71
    CCI (20d)43.3
    MFI (14d)62.4

    Volatility Measures

    ATR (14d)$2.09(4.3%)
    StdDev (20d)2.08
    Hist Vol41.2%(High)

    Volume Flow

    VWAP$48.38
    OBV95.8M
    AD Line75.1M
    CMF (20d)0.261

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio1.5x
    VWMA (20d)$47.60

    Pivot Points

    R3$50.61
    R2$50.06
    R1$49.39
    Pivot Point$48.84
    S1$48.17
    S2$47.62
    S3$46.95

    Advanced Oscillators

    TSI26.17
    Ultimate Osc59.2
    KST155.78

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$5.84M$3.56M$5.57M$3.70M$5.26M$1.57M$5.22M$2.29M$11.13M$8.48M$6.69M$1.41M
    Cost of Revenue$350,000$219,000$435,000$398,000$656,000$197,000$619,000$264,000$234,000$150,000$65,000$0
    Gross Profit$5.49M$3.34M$5.13M$3.30M$4.61M$1.37M$4.60M$2.02M$10.89M$8.34M$6.62M$1.41M
    Operating Expenses$57.69M$49.06M$56.25M$54.34M$48.47M$40.70M$50.43M$42.25M$54.90M$62.56M$68.37M$83.28M
    R&D$33.96M$29.18M$34.78M$34.37M$35.38M$36.14M$38.84M$30.59M$33.66M$40.69M$42.62M$65.40M
    SG&A$25.33M$21.52M$23.46M$21.48M$15.69M$12.87M$13.57M$13.49M$16.00M$14.17M$18.50M$18.30M
    Operating Income$-52,203,000$-45,720,000$-51,118,000$-51,035,000$-43,865,000$-39,331,000$-45,828,000$-40,228,000$-44,010,000$-54,228,000$-61,748,000$-81,877,000
    Interest Income$5.05M$5.23M$5.81M$3.50M$3.52M$4.13M$4.24M$4.87M$5.80M$6.51M$7.17M$7.50M
    Interest Expense$14.37M$14.03M$14.57M$16.72M$15.59M$15.11M$14.88M$16.61M$16.16M$16.10M$15.71M$15.44M
    Income Before Tax$-79,218,000$-53,047,000$-41,002,000$-71,903,000$-37,294,000$-43,141,000$-72,405,000$-44,409,000$-55,351,000$-64,962,000$-70,172,000$-89,640,000
    Income Tax Expense$1.84M$488,000$-3,916,000$8.63M$425,000$496,000$856,000$-31,000$948,000$656,000$3.03M$-69,000
    Net Income$-81,059,000$-53,535,000$-37,086,000$-80,529,000$-37,719,000$-43,637,000$-73,261,000$-44,378,000$-56,299,000$-65,618,000$-73,206,000$-89,571,000
    EBITDA$-68,568,000$-45,624,000$-33,644,000$-56,981,000$-23,643,000$-29,749,000$-59,838,000$-31,478,000$-45,306,000$-56,439,000$-61,830,000$-83,786,000
    EBIT$-69,903,000$-44,245,000$-32,242,000$-58,685,000$-25,227,000$-32,159,000$-61,765,000$-32,664,000$-44,999,000$-55,373,000$-61,630,000$-81,691,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about QURE

    News

    Certain Ordinary Shares of uniQure N.V. are subject to a Lock-Up Agreement Ending on 23-AUG-2026.

    This article announces that certain ordinary shares of uniQure N.V. are subject to a lock-up agreement ending on August 23, 2026. These shares will be under lock-up for 61 days, starting from June 23, 2026. The agreement restricts executive officers and directors from selling or transferring ordinary shares or convertible securities during this period.

    www.marketscreener.com•8/23/26•
    Neutral

    Certain Options of uniQure N.V. are subject to a Lock-Up Agreement Ending on 23-AUG-2026.

    Certain options of uniQure N.V. are under a lock-up agreement that will expire on August 23, 2026. This agreement restricts the sale or transfer of ordinary shares or convertible securities by executive officers and directors for a 60-day period, commencing on June 23, 2026.

    www.marketscreener.com•8/23/26•
    Neutral

    uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

    uniQure (QURE) reported a Q1 loss of $0.85 per share, surpassing the Zacks Consensus Estimate of a $0.88 loss, marking an earnings surprise of +2.86%. However, the company missed revenue estimates, posting $3.56 million against an expected higher figure. The stock currently holds a Zacks Rank #4 (Sell), indicating potential underperformance in the near future.

    Eastern Progress•8/22/26•
    Somewhat-Bearish

    Price to sales forward of uniQure N.V. – NASDAQ:QURE

    This article provides the forward price-to-sales ratio for uniQure N.V. (NASDAQ: QURE). It appears to be a financial data snippet from TradingView, showing the period, value, and change metrics for this specific financial indicator. The content indicates that the data is compiled by humans and sourced from ICE Data Services and FactSet.

    TradingView•8/22/26•
    Neutral

    Royal Bank of Canada Increases Stock Position in uniQure N.V. $QURE

    Royal Bank of Canada significantly increased its stake in uniQure N.V. by 26% in the first quarter, now owning 107,888 shares valued at $1.76 million. Despite uniQure reporting a wider-than-expected loss per share, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $65.00. Institutional investors collectively hold 78.83% of the company's stock, though some insiders have recently sold shares through pre-arranged trading plans.

    MarketBeat•8/19/26•
    Somewhat-Bullish

    Frequently Asked Questions About QURE

    Does QURE pay dividends?
    Uniqure NV (QURE) does not currently pay a regular dividend.
    What is QURE's market cap?
    Uniqure NV (QURE) has a market capitalization of $3.38B with a current stock price of $48.68.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In